Lazertinib( YH 25448 | YH25448 | GNS-1480 | GNS1480 )

Catalog No. M12983 CAS No. 1903008-80-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Lazertinib
Note

Research use only, not for human use.
Brief Description

Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.
Description

Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations; shows the beneficial for the NSCLC with brain metastasis.Lung Cancer Phase 2 Clinical.
In Vitro

——
In Vivo

——
Synonyms

YH 25448 | YH25448 | GNS-1480 | GNS1480
Pathway

Angiogenesis
Target

EGFR
Recptor

EGFR (del19)|EGFR (T790M)|EGFR (T790M/L858R)
Research Area

Cancer
Indication

Lung Cancer

CAS Number

1903008-80-9
Formula Weight

554.66
Molecular Formula

C30H34N8O3
Purity

>98% (HPLC)
Solubility

Ethanol: Insoluble; Water: Insoluble; DMSO: 10 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
SMILES

C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
Chemical Name

N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide

1. Patent US20160102076 A1. 2.?Yun J, et al. Clin Cancer Res. 2019 Jan 22. pii: clincanres.2906.2018. doi: 10.1158/1078-0432.CCR-18-2906.

Calculator

molnova catalog